SCL-1
SCL-1 is an orally active anti-PD-1/PD-L1 inhibitor. SCL-1 can inhibit PD-1/PD-L1 binding. SCL-1 increases T cells, B cells and natural killer cells. SCL-1 exerts strong tumor growth inhibitory effects that were mediated by effector T-cell induction inside tumors and the up-regulated expression of long non-coding RNAs as neoantigens leading to cytotoxic T lymphocyte activation. SCL-1 can be used for the research of cancer, such as triple-negative breast cancer[1][2].
Product Specifications
CAS Number
1061105-16-5
UNSPSC
12352100
Target
PD-1/PD-L1
Related Pathways
Immunology/Inflammation
Field of Research
Cancer
Smiles
CC1CCCCN1C(C2CCN(CC2)C3=NN4C(C=C3)=NN=C4C(F)(F)F)=O
Molecular Formula
C18H23F3N6O
Molecular Weight
396.41
References & Citations
[1]Ikeya T, et al. Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse model. Sci Rep. 2025 Jul 24;15 (1) :26918.|[2]Akiyama Y, et al. Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding. Anticancer Res. 2022 Nov;42 (11) :5233-5247.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
ARP53446_P050-FITC 100 µL
Phactr3 Antibody - middle region : FITC (ARP53446_P050-FITC)
Sign In for Pricing
View Details 
MBS081325 Inquire
Chicken Glutathione S Transferase Alpha 2 ELISA Kit
Sign In for Pricing
View Details